However, it is notable that no co-occurrence of the EML4::ALK fusion with EGFR mutations was observed, confirming the mutual exclusion of the two key driver alterations in NSCLC [3,19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.